Register for Upcoming Webinar on DEC. 8 @ 11AM

2024 China NMPA Bluebook is here:

Why This Chinese Fund Is Seeking Medical Device Investment Opportunities


“We are more interested in investing in innovative medical devices, which has a greater chance of finding value in companies making ‘small and beautiful’ products.” Ke Zhang, a Tronfund partner said a recent interview.

Founded in 2011 in Shanghai, China, Tronfund has been focused in investing in innovative medical device companies including medical treatment equipment and healthcare services;

In less than 6 years since inception, the size of Tronfund has reached over RMB 7 billion yuans (or about USD $1 billion). Its partners such as Ke Zhang have worked in Pfizer, Johnson & Johnson, AstraZeneca and other well-known international pharmaceutical and medical device companies, for more than 20 years.

Zhang is now investing in nearly ten projects with the focus in medical devices,, the cumulative of his investment portfolio has reached to more than RMB 1.5 billion yuans.

Zhang also noted “compared to the pharmaceutical industry, it is easier for innovators in medical device field to create ‘small and beautiful’ products in a niche, by differentiating their products from others to obtain higher growth thus margins. From the market capacity point of view, the ratio of pharma vs medical device in the US is 1:1, whereas in China’s this radio is only 5: 1. In other words, China’s pharmaceutical market is five times the device market. We expect a huge growth potential in the medical device market!”

China Med Device, LLC, specializes in funding and growth acceleration services for medical device companies, and market consulting and China entry acceleration for your medical device. Please contact us at or visit us at

Have Questions?

Related Services


Recent Events

Related Posts


Get Updated

Receive Updates in Your Inbox